AbbVie Australia has announced
that Viekira Pak (ombitasvir,
paritaprevir, ritonavir tablets;
dasabuvir tablets) and Viekira
Pak-RBV (ombitasvir/paritaprevir/
ritonavir tablets; dasabuvir tablets
with ribavirin) will be listed on the
Pharmaceutical Benefits Scheme
(PBS) from 01 May for chronic
hepatitis C patients under certain
circumstances.
The listing fills a gap for some
patients who are not suitable
to receive existing treatment
regimens, said Associate Professor
Amany Zekry, Gastroenterological
Society of Australia.The above article was sent to subscribers in Pharmacy Daily's issue from 18 Apr 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Apr 16
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.